NVDL:OTO-Novadel Pharma Inc (USD)

ETF | Others | OTC Pink

Last Closing

USD 46.3

Change

-0.48 (-1.03)%

Market Cap

USD 0.98M

Volume

0.01B

Analyst Target

USD 1.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NovaDel Pharma Inc. is a pharmaceutical Company, which develops oral spray formulations for a range of marketed pharmaceuticals.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-03-25 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
IBIT iShares Bitcoin Trust

-1.88 (-3.80%)

USD 50.95B
QQQM Invesco NASDAQ 100 ETF

-5.16 (-2.60%)

USD 39.48B
JEPQ JPMorgan Nasdaq Equity Premium..

-1.17 (-2.21%)

USD 22.06B
ACWI iShares MSCI ACWI ETF

-2.04 (-1.72%)

USD 18.95B
CGABL The Carlyle Group Inc. 4.625% ..

-0.13 (-0.74%)

USD 16.14B
SNDK Sandisk Corp

-3.91 (-7.39%)

USD 5.99B
TBIL Rbb Fund Inc - Us Treasury 3 M..

N/A

USD 5.17B
TSLL Direxion Shares ETF Trust - Di..

-0.77 (-7.25%)

USD 3.11B
ETHA iShares Ethereum Trust ETF

-1.01 (-6.66%)

USD 2.37B
USCL iShares Climate Conscious & Tr..

-1.38 (-2.02%)

USD 2.33B

ETFs Containing NVDL

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -30.26% 7% C- 18% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -30.26% 7% C- 18% F
Trailing 12 Months  
Capital Gain 5.71% 69% C- 65% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 5.71% 60% D- 61% D-
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 157.76% 98% N/A 94% A
Dividend Return 157.76% 98% N/A 94% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 184.71% 4% F 12% F
Risk Adjusted Return 85.41% 88% B+ 93% A
Market Capitalization 0.98M 98% N/A 86% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative earnings

The company had negative total earnings in the most recent four quarters.